Characteristics at enrolment | Study subjects | HCC cases | Incidence Rate/105 (95 % CI) | Hazard Ratios (95 % CI)b |
---|---|---|---|---|
No. | No. | |||
Total | 4492 | 22 | 63.3 (41.7–96.2) | |
Gender | ||||
Female | 2482 | 10 | 51.4 (27.6–95.5) | 1* |
Male | 2010 | 12 | 78.5 (44.6–138.3) | 1.2 (0.5–2.7) |
Age at testing (years) | ||||
< 60 | 3349 | 3 | 11.3 (3.6–35.0) | 1* |
60–69 | 551 | 9 | 214.7 (111.7–412.6) | 7.5 (1.8–30.8) |
≥ 70 | 592 | 10 | 252.8 (136.0–469.8) | 6.8 (1.6–29.3) |
Chronic HCV/HBV infections** | ||||
Anti HCV-negative/HBsAg-negative | 4065 | 2 | 6.3 (0.8–22.8) | 1* |
HCV RNA-negative/HBsAg-positive | 95 | 3 | 403.3 (83.2–1179) | 75.0 (12.3–456.5) |
HCV RNA-positive/HBsAg-negative | 239 | 15 | 909.3 (509.0–1500) | 61.8 (13.3–286.4) |
HCV RNA-positive/HBsAg-positive | 4 | 0 | 0.0 (0.0–11,938) | 0.0 (0.0-∞) |
γ-glutamyl transferase (γGT) U/La | ||||
≤ 30 | 3588 | 9 | 32.2 (16.8–61.9) | 1* |
31–90 | 784 | 5 | 83.9 (34.9–201.6) | 1.5 (0.5–4.7) |
> 90 | 116 | 8 | 1006 (503.0–2011) | 10.3 (3.6–29.2) |
Alanine transaminase (ALT) U/La | ||||
≤ 40 | 3954 | 8 | 26.1 (13.1–52.2) | 1* |
41–120 | 490 | 9 | 240.1 (125.0–461.5) | 4.1 (1.5–11.4) |
> 120 | 45 | 5 | 1598 (665–3840) | 10.3 (3.2–33.3) |
Aspartate aminotransferase (AST) U/La | ||||
≤ 40 | 4294 | 6 | 18.0 (8.1–40.0) | 1* |
41–120 | 170 | 11 | 885.1 (490.2–1598) | 9.4 (3.1–28.8) |
> 120 | 25 | 5 | 3539 (1473–8501) | 27.4 (7.6–98.0) |
Platelet count (103/μl)a | ||||
220–700 | 2253 | 2 | 11.4 (1.4–41.1) | 1* |
< 220 | 2203 | 20 | 118.4 (72.3–182.8) | 50.0 (1.0–100.0) |
FIB-4a | ||||
< 1.45 | 3552 | 1 | 3.6 (0.5–25.4) |
|
1.45–3.25 | 774 | 5 | 88.3 (36.8–212.2) | |
> 3.25 | 130 | 16 | 1889 (1157–3083) | 17.6 (6.2–49.7) |